During its October 19–22, 2015 meetings, the Committee for Medicinal Products for Human Use ("CHMP") recommended extensions of indication for  Cubicin, Edurant, Emend, Volibris, Xalkori, and two extensions of indication for Cosentyx.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.